Hepatocellular Carcinoma Clinical Trial
— SELECTOfficial title:
Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial
This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and
safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced
hepatocellular carcinoma (HCC) patients compared with sorafenib alone, and to determine the
prognostic factors that influence the survival.
Data on the efficacy and safety of sorafenib in combination with TACE in patients with
advanced HCC are lacking. Because in western countries, advanced HCC is considered as a
contraindication for TACE treatment. However, clinical practice patterns differ markedly
between Asia and western countries: in Asia TACE is performed in selected advanced HCC
patients. We consider sorafenib combined with TACE could achieve better survival benefit than
sorafenib alone in selected advanced HCC patients.
Status | Recruiting |
Enrollment | 246 |
Est. completion date | December 2020 |
Est. primary completion date | September 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Prior informed consent 2. Advanced stage HCC/ Barcelona Clinic Liver Cancer(BCLC) C stage 3. Confirmed Diagnosis of HCC: 1. Cirrhotic subjects: Clinical diagnosis by Asian Pacific Association for the Study of the Liver(AASLD) criteria. 2. Non-cirrhotic subjects: for subjects without cirrhosis, histological or cytological confirmation is mandatory 3. Documentation of original biopsy for diagnosis is acceptable 4. Child Pugh class A without ascites or hepatic encephalopathy 5. Eastern Cooperative Oncology Group(ECOG) Performance Status of 0-1 6. At least one uni-dimensional lesion measurable by CT-scan or MRI according to the RECIST, mRECIST and EASL criteria,respectively 1. single lesion>5cm 2. 2-3 lesions, at least one lesion>3cm if more than 4 lesions, no limitation of the tumor size, but the sum of size of all tumor lesions should be less than 50% of liver parenchyma. 7. Male or female subjects = 18 years of age 8. Ability to swallow oral medications 9. Life expectancy of at least 12 weeks 10. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 4 weeks after the completion of trial 11. Adequate bone marrow, liver and renal function as assessed by central lab by means of the following laboratory requirements from samples within 7 days prior to randomization: 1. Hemoglobin > 9.0 g/dl 2. Absolute neutrophil count (ANC) >1,500/mm3 3. Platelet count=50x109/L 4. ALB=28g/L 5. Total bilirubin < 2 mg/dL 6. Alanine aminotransferase(ALT) and aspartate aminotransferase(AST) < 5 x upper limit of normal 7. Blood urea nitrogen(BUN) and creatinine < 1.5 x upper limit of normal 8. International normalized ratio(INR) < 1.7, or prothrombin time(PT) < 4 seconds above control Exclusion Criteria: 1. Diffuse HCC or tumor burden =50% of liver parenchyma 2. Main portal vein obstruction, vascular invasion in hepatic vein or inferior vena cava 3. Presence of metastasis in biliary tract,brain or bone 4. Poor blood supply for the liver tumor lesions; poor blood supply refers that the tumor lesions fail to show obvious contrast uptake in the arterial phase and washout in venous or late phases by CT scan or MRI 5. Any contraindications for hepatic embolization procedures: 1. Known hepatofugal blood flow 2. Known porto-systemic shunt 3. Renal failure / insufficiency requiring hemo-or peritoneal dialysis 6. Target lesions having previously been treated with local therapy such as resection of HCC, radiofrequency ablation (RFA), percutaneous ethanol injection (PEI) 7. Other molecular target drugs ongoing or completed < 4 weeks prior to the baseline scan 8. Prior transarterial embolization or systemic chemotherapy 9. Any = CTC adverse events(AEs) grade 2 acute toxic effects of any prior local treatment 10. Patients with untreated varices or active bleeding 11. History of cardiac disease: 1. Congestive heart failure >New York Heart Association (NYHA) class 2 2. Uncontrolled hypertension 12. Known history of HIV infection 13. Active clinically serious infections (> grade 2 NCI-CTCAE Version 3.0), except for Hepatitis B virus(HBV) and hepatitis C virus(HCV) infection 14. Clinically significant gastrointestinal bleeding within 4 weeks prior to start of study drug 15. Thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months prior to the first dose of study drug 16. Previous or concurrent cancer that is distinct in primary site or histology from HCC. Any cancer curatively treated >3 years prior to entry is permitted 17. Any contraindication for sorafenib or doxorubicin administration 18. Pregnant or breast-feeding subjects 19. Any disease(within 6 months of randomization)which could affect the evaluation of the study drug 20. Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study 21. Major surgery within 4 weeks prior to start of study drug (e.g. thoracolaparotomy is not allowed, but noninvasive surgery, e.g. biopsy, is allowed) 22. Autologous bone marrow transplant or stem cell rescue within 1 year prior to start of study drug 23. History of organ allograft |
Country | Name | City | State |
---|---|---|---|
China | Xijing Hospital of Digestive Disease | Xi`an | Shaanxi |
Lead Sponsor | Collaborator |
---|---|
Fourth Military Medical University |
China,
Zhao Y, Wang WJ, Guan S, Li HL, Xu RC, Wu JB, Liu JS, Li HP, Bai W, Yin ZX, Fan DM, Zhang ZL, Han GH. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013 Jul;24(7):1786-92. doi: 10.1093/annonc/mdt072. Epub 2013 Mar 18. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | AFP response | The clinical laboratory will use the electrochemiluminescence immunoassay method to determine the value of AFP. (Elecsys Cobas e601, Roche) ?AFP(%) = [(AFPbaseline-AFPpost-treatment)/ AFPbaseline]×100%; AFP response =?AFP(%) > AFP response cutoff point | The AFP response will be assessed up to 2.5 years. | |
Primary | Overall survival | Overall survival (OS) analysis is measured from the time of randomization until death occurred from any cause. | The final analysis will occur when the expected number of death (173 events) is reached. Up to 2.5 years | |
Secondary | Time to progression | The time to progression is measured from the time of randomization to the radiologically confirmed progression. | The time to progression will be assessed at the end of the study, up to 2.5 years | |
Secondary | Tumor response | Tumor response will be evaluated according to RECIST, mRECIST and EASL criteria, respectively. Tumor response will be presented in the terms of complete response, partial response, stable disease and progression disease. | Tumor response will be assessed up to 2.5 years | |
Secondary | Adverse events | The terms and grade of adverse events will be presented according to the Common Terminology Criteria for Adverse Events(CTCAE:version 4.0) | The adverse events will be assessed up to 2.5 years. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |